Progress of Antiviral Research of Arbidol

BAI Jiawei; MA Chengtai; WEI Jie; WU Miao; DU Xianjin

doi:10.14009/j.issn.1672-2124.2022.04.028

您当前的位置：

首页 >

文章列表页 >

Progress of Antiviral Research of Arbidol

更新时间：2022-10-08

- Progress of Antiviral Research of Arbidol
- Vol. 22, Issue 4, Pages: 508-512(2022)
- 作者机构：
  
  1. 武汉大学人民医院重症医学科
  2. 武汉大学人民医院急诊科
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2022.04.028
  CLC： R978.7
- Published：2022，
扫描看全文
BAI Jiawei, MA Chengtai, WEI Jie, et al. Progress of Antiviral Research of Arbidol. [J]. 22(4):508-512(2022)
DOI：

BAI Jiawei, MA Chengtai, WEI Jie, et al. Progress of Antiviral Research of Arbidol. [J]. 22(4):508-512(2022) DOI： 10.14009/j.issn.1672-2124.2022.04.028.

摘要

阿比多尔是一种非核苷类广谱抗病毒药，主要通过抑制病毒进入细胞和调节免疫发挥抗病毒作用。大量研究结果证实，阿比多尔对多种病毒具有抗病毒活性，包括DNA病毒和RNA病毒，包膜和非包膜病毒，但其在我国主要用于治疗由A型、B型流感病毒等引起的上呼吸道感染。新型冠状病毒肺炎(COVID-19)疫情暴发后，体内外实验结果证实，阿比多尔对新型冠状病毒(SARS-CoV-2)有明显抑制作用，使用阿比多尔可改善患者临床结局，但也有报道指出阿比多尔无确切疗效。阿比多尔作为一种潜在有效的抗病毒药还需大量临床实践证实。

Abstract

Arbidol is a kind of non-nucleoside broad-spectrum antiviral drugs

which plays an antiviral role mainly by inhibiting the entry of virus into cells and regulating immunity. A large number of experiments have confirmed the antiviral activity of arbidol against a variety of viruses

including DNA and RNA viruses

enveloped and non-enveloped viruses. In China

arbidol is mainly used for the treatment of upper respiratory tract infection caused by influenza A and B virus. After the outbreak of COVID-19 pandemic

the results of in vitro and in vivo experiments confirmed that arbidol has significant inhibitory effects on SARS-CoV-2

and the use of arbidol can improve the clinical outcomes of patients

yet there are also reports shows that arbidol has no definite curative efficacy. As a kind of potentially effective antiviral drugs

arbidol still needs a lot of clinical practice confirmation.

关键词

阿比多尔抗病毒流感病毒新型冠状病毒肺炎

Keywords

ArbidolAntiviral drugsInfluenza virusCOVID-19

references

查看原文

Views

154

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Retrospective Analysis of Clinical Characteristics and Whole Process of Integrated Traditional Chinese and Western Medicine Treatment for 20 Patients with COVID-19

Systematic Review of Efficacy and Safety of Lopinavir/Ritonavir in Patients with COVID-19

Application of Traditional Chinese Medicine Injection in the Treatment of COVID-19

Mechanism of Ganlu Xiaodu Decoction on COVID-19 Treatment Based on Network Pharmacology

Analysis on Application of Antiviral Drugs in 51 Patients with COVID-19

Related Author

陈灵

柳芳

夏杨

宋红艳

夏敬胜

卢江

陈永刚

WU Xiayang

Related Institution

Dept. of Pharmacy, China-Japan Friendship Hospital

Tongren Hospital of Wuhan University

Dept.of Pharmacy,Xiamen Children’s Hospital

Dept.of Pharmacy,Guang’anmen Hospital of China Academy of Chinese Medical Sciences

Dept.of Pharmacy,Wuhan Third Hospital/Tongren Hospital of Wuhan University

⁰